v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
REVENUES:    
Product revenue $ 2,593,163 $ 2,088,178
License and other revenue 35,708 35,708
Total Revenues 2,628,871 2,123,886
OPERATING EXPENSES    
Cost of product revenue 1,616,287 1,266,421
Research and development 1,192,727 2,027,712
Plasma centers 1,479,476 1,280,419
General and administrative 4,277,384 1,707,870
TOTAL OPERATING EXPENSES 8,565,874 6,282,422
LOSS FROM OPERATIONS (5,937,003) (4,158,536)
OTHER INCOME (EXPENSE):    
Interest income 18,568 13,508
Interest expense (618,528) (467,441)
OTHER EXPENSE, NET (599,960) (453,933)
NET LOSS $ (6,536,963) $ (4,612,469)
NET LOSS PER COMMON SHARE - Basic and Diluted $ (0.51) $ (0.43)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted 12,886,741 10,710,587

Source